Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Consent of parent or legal guardian required~* Chronic HCV infection~* Screening laboratory values within defined thresholds~* Individuals must have a determination of prior treatment status:~  * DAA-naive is defined as either:~    * Treatment naive with no prior exposure to any interferon (IFN), ribavirin (RBV), or approved or experimental HCV-specific DAA~   * Treatment experienced with an IFN-based regimen and no prior exposure to an approved or experimental HCV-specific DAA~ * DAA-experienced is defined as prior exposure to a regimen including any DAA (eg, non-structural protein (NS)3/4A protease inhibitor, NS5A inhibitor, or NS5B nucleotide/nucleoside inhibitor)~Key Exclusion Criteria:~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol~* Co-infection with human immunodeficiency virus (HIV), acute hepatitis A virus (HAV) or hepatitis B virus (HBV)~* Clinical hepatic decompensation (eg, clinical ascites, encephalopathy, and/or variceal hemorrhage)~* Pregnant or nursing females~* Known hypersensitivity to study medication~* Use of any prohibited concomitant medications as within 28 days of the Day 1 visit~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Experimental: Cohort 1 (12 to < 18 years old), 8 Weeks (Type: EXPERIMENTAL): Direct-acting antiviral (DAA)-naive participants without cirrhosis in Cohort 1 (12 to \< 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 8 weeks.
- Experimental: Cohort 1 (12 to < 18 years old), 12 Weeks (Type: EXPERIMENTAL): DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 1 (12 to \< 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 12 weeks.
- Experimental: Cohort 2 (6 to < 12 years old), 8 Weeks (Type: EXPERIMENTAL): DAA-naive participants without cirrhosis in Cohort 2 (6 to \< 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
- Experimental: Cohort 2 (6 to < 12 years old), 12 Weeks (Type: EXPERIMENTAL): DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 2 (6 to \< 12 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
- Experimental: Cohort 3 (3 to < 6 years old), 8 Weeks (Type: EXPERIMENTAL): DAA-naive participants without cirrhosis in Cohort 3 (6 to \< 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
- Experimental: Cohort 3 (3 to < 6 years old), 12 Weeks (Type: EXPERIMENTAL): DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 3 (3 to \< 6 years old) will receive SOF/VEL/VOX FDC for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility